Glofitamab
- Generic Name
- Glofitamab
- Brand Names
- Columvi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2229047-91-8
- Unique Ingredient Identifier
- 06P3KLK2J8
- Background
Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.
...
- Indication
Glofitamab is indicated in Canada for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T c...
- Associated Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Associated Therapies
- -
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT04970901
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸Memorial Cancer Institute - Memorial Hospital West, Pembroke Pines, Florida, United States
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 80
- Registration Number
- NCT04914741
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
CAR-T Followed by Bispecific Antibodies
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT04889716
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT04657302
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
🇨🇳Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou City, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 270
- Registration Number
- NCT04408638
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Terapii Komórkowych i Chorób Wewn?trznych, Wroc?aw, Poland
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Community Cancer Institute (CCI), Fresno, California, United States
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT04313608
- Locations
- 🇦🇺
Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
🇦🇺Monash Health Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma
- Conditions
- Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaT-Cell/Histiocyte-Rich Large B-Cell LymphomaGray-Zone Lymphoma
- Interventions
- Drug: Polatuzumab VedotinBiological: RituximabDrug: PrednisoneDrug: EtoposideDrug: DoxorubicinDrug: CyclophosphamideProcedure: Multigated Acquisition ScanBiological: GlofitamabProcedure: EchocardiographyProcedure: FDG-Positron Emission TomographyProcedure: Computed TomographyProcedure: Bone Marrow BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 56
- Registration Number
- NCT04231877
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 18
- Registration Number
- NCT04161248
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
🇨🇦The Jewish General Hospital, Montreal, Quebec, Canada
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 498
- Registration Number
- NCT04077723
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇧🇪UZ Gent, Gent, Belgium
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 211
- Registration Number
- NCT03533283
- Locations
- 🇧🇪
UZ Gent, Gent, Belgium
🇺🇸Novant Health Cancer Institute, Charlotte, North Carolina, United States
🇩🇰Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.